obesity drug - Search News

Roche, Zealand Pharma and obesity

Reuters on MSN · 10h

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital increase.

Bloomberg · 15h

Roche, Zealand Pharma in $5.3 Billion Pact for Obesity Drugs

Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss drugmaker’s effort to get into a hot market dominated by Novo Nordisk A/S and Eli Lilly & Co.

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on Way.

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

The Wall Street Journal on MSN · 1d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Barron's on MSN · 7h

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on the Way.

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

Zacks.com on MSN10h

VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply

The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...

2don MSN

Is the obesity drug market still a duopoly?

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

18h

Employers face pressure to add coverage of Ozempic, other weight-loss drugs

Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results